Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial
CardioVascular and Interventional Radiology · 2023
DOI: 10.1007/s00270-022-03338-1 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift CardioVascular and Interventional Radiology, 2023. Verfasst von T M L Tong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Leiden University Medical Center, Postal Zone C7-P, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Nivolumab, Melphalan. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Delcath Systems Inc..
Abstract (Originalsprache)
PURPOSE: To define a safe treatment dose of ipilimumab (IPI) and nivolumab (NIVO) when applied in combination with percutaneous hepatic perfusion with melphalan (M-PHP) in metastatic uveal melanoma (mUM) patients (NCT04283890), primary objective was defining a safe treatment dose of IPI/NIVO plus M-PHP. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAEv4.03). Secondary objective was response rate, PFS and OS. MATERIALS AND METHODS: Patients between 18-75 years with confirmed measurable hepatic mUM according to RECIST 1.1 and WHO performance score 0-1 were included. Intravenous IPI was applied at 1 mg/kg while NIVO dose was increased from 1 mg/kg in cohort 1 to 3 mg/kg in cohort 2. Transarterial melphalan dose for M-PHP was 3 mg/kg (maximum of 220 mg) in both cohorts. Treatment duration was 12 weeks, consisting of four 3-weekly courses IPI/NIVO and two 6-weekly M-PHPs. RESULTS: Seven patients were included with a median age of 63.6 years (range 50-74). Both dose levels were well tolerated without dose-limiting toxicities or deaths. Grade III/IV adverse events (AE) were observed in 2/3 patients in cohort 1 and in 3/4 patients in cohort 2, including Systemic Inflammatory Response Syndrome (SIRS), febrile neutropenia and cholecystitis. Grade I/II immune-related AEs occurred in all patients, including myositis, hypothyroidism, hepatitis and dermatitis. There were no dose-limiting toxicities. The safe IPI/NIVO dose was defined as IPI 1 mg/kg and NIVO 3 mg/kg. There was 1 complete response, 5 partial responses and 1 stable disease (3 ongoing responses with a median FU of 29.1 months). CONCLUSION: Combining M-PHP with IPI/NIVO was safe in this small cohort of patients with mUM at a dose of IPI 1 mg/kg and NIVO 3 mg/kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Leiden University Medical Center, Postal Zone C7-P, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Anesthesiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Extra Corporal Circulation, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Medical Oncology, Leiden University Medical Center, Postal Zone C7-P, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. h.w.kapiteijn@lumc.nl.
Förderung
- Bristol-Myers Squibb
- Delcath Systems Inc.
Zitieren
APA
Tong, T. M. L., Burgmans, M. C., Speetjens, F. M., van Erkel, A. R., van der Meer, R. W., van Rijswijk, C. S. P., Jonker-Bos, M. A., Roozen, C. F. M., Sporrel-Blokland, M., Lutjeboer, J., van Persijn van Meerten, E. L., Martini, C. H., Zoethout, R. W. M., Tijl, F. G. J., Blank, C. U., & Kapiteijn, E. (2023). Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-022-03338-1
Vancouver
Tong TML, Burgmans MC, Speetjens FM, van Erkel AR, van der Meer RW, van Rijswijk CSP, et al. Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial. CardioVascular and Interventional Radiology. 2023. doi:10.1007/s00270-022-03338-1
BibTeX
@article{Tong2023,
author = {Tong, T M L and Burgmans, M C and Speetjens, F M and van Erkel, A R and van der Meer, R W and van Rijswijk, C S P and Jonker-Bos, M A and Roozen, C F M and Sporrel-Blokland, M and Lutjeboer, J and van Persijn van Meerten, E L and Martini, C H and Zoethout, R W M and Tijl, F G J and Blank, C U and Kapiteijn, E},
title = {Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial},
journal = {CardioVascular and Interventional Radiology},
year = {2023},
doi = {10.1007/s00270-022-03338-1}
}
EUVIMED